首页> 外文期刊>癌症生物学与医学:英文版 >The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics
【24h】

The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics

机译:M6A甲基化景观将肝细胞癌分层为3个亚型,具有不同的代谢特征

获取原文
获取原文并翻译 | 示例
       

摘要

Objective:Epigenetic aberration plays an important role in the development and progression of hepatocellular carcinoma(HCC).However,the alteration of RNA N6-methyladenosine(m6A)modifications and its role in HCC progression remain unclear.We therefore aimed to provide evidence using bioinformatics analysis.Methods:We comprehensively analyzed the m6A regulator modification patterns of 605 HCC samples and correlated them with metabolic alteration characteristics.We elucidated 390 gene-based m6A-related signatures and defined an m6Ascore to quantify m6A modifications.We then assessed their values for predicting prognoses and therapeutic responses in HCC patients.Results:We identified 3 distinct m6A modification patterns in HCC,and each pattern had distinct metabolic characteristics.The evaluation of m6A modification patterns using m6Ascores could predict the prognoses,tumor stages,and responses to sorafenib treatments of HCC patients.A nomogram based on m6Ascores showed high accuracy in predicting the overall survival of patients.The area under the receiver operating characteristic curve of predictions of 1,3,and 5-year overall survivals were 0.71,0.69,and 0.70 in the training cohort,and in the test cohort it was 0.74,0.75,and 0.71,respectively.M6Acluster C1,which corresponded to hypoactive mRNA methylation,lower expression of m6A regulators,and a lower m6Ascore,was characterized by metabolic hyperactivity,lower tumor stage,better prognosis,and lower response to sorafenib treatment.In contrast,m6Acluster C3 was distinct in its hyperactive mRNA methylations,higher expression of m6A regulators,and higher m6Ascores,and was characterized by hypoactive metabolism,advanced tumor stage,poorer prognosis,and a better response to sorafenib.The m6Acluster,C2,was intermediate between C1 and C3.Conclusions:HCCs harbored distinct m6A regulator modification patterns that contributed to the metabolic heterogeneity and diversity of HCC.Development of m6A gene signatures and the m6Ascore provides a more comprehensive understanding of m6A modifications in HCC,and helps predict the prognosis and treatment response.
机译:目的:表观遗传像差在肝细胞癌(HCC)的开发和进展中起着重要作用。然而,RNA N6-甲基腺苷(M6A)修饰的改变及其在HCC进展中的作用仍然不清楚。因此,我们旨在使用生物信息学提供证据分析。我们综合分析了605个HCC样品的M6A调节器改性模式,并与代谢改变特征相关联。我们阐明了390个基因的M6A相关象征并定义了M6A修改的M6Ascore。我们评估了它们的预测值在HCC患者中的预后和治疗反应。结果:我们在HCC中鉴定了3个不同的M6A改性模式,每个模式具有不同的代谢特征。使用M6Ascorouges的M6A改性模式的评估可以预测对索拉非尼治疗的预后,肿瘤阶段和反应HCC患者。基于M6ASCORORORORORA的ROM图显示了PR的高精度针对患者的整体存活率。接收器的接收器经营特征曲线的预测1,3和5年的整体幸存者为0.71,0.69,培训队列中的0.70.70.75,而且在测试队列中,它为0.74,0.75和0.71分别为0.71分别,其对应于低温mRNA甲基化,低表达的M6a调节剂和较低的M6Ascore,其特征在于代谢多动,下肿瘤阶段,更好的预后和对Sorafenib治疗的较低反应。对比, M6Acluster C3在其过度活跃的mRNA甲基化中是不同的,M6a调节剂的表达更高,较高的M6Ascorous,并以低钾代谢,晚期肿瘤阶段,预后和对索拉非尼的更好反应而表现为特征.M6Acluster C2是C1之间的中间体和C3.CONCLUSIONS:HCCS有助于HCC的代谢异质性和多样性的不同M6A调节器改性模式.M6A基因签名和M6ASCORE的代谢异质性和多样性提供了对HCC中M6A修改的更全面的了解,并有助于预测预后和治疗响应。

著录项

  • 来源
    《癌症生物学与医学:英文版》 |2020年第004期|P.937-952|共16页
  • 作者单位

    Department of General Surgery Huashan Hospital&Cancer Metastasis Institute&Institutes of Biomedical Sciences Fudan University Shanghai 250040 ChinaInstitutes of Biomedical Sciences Fudan University Shanghai 200032 China;

    Department of General Surgery Huashan Hospital&Cancer Metastasis Institute&Institutes of Biomedical Sciences Fudan University Shanghai 250040 ChinaInstitutes of Biomedical Sciences Fudan University Shanghai 200032 China;

    Shanghai Medical College Fudan University Shanghai 200040 China;

    Department of General Surgery Huashan Hospital&Cancer Metastasis Institute&Institutes of Biomedical Sciences Fudan University Shanghai 250040 ChinaInstitutes of Biomedical Sciences Fudan University Shanghai 200032 China;

    Department of General Surgery Huashan Hospital&Cancer Metastasis Institute&Institutes of Biomedical Sciences Fudan University Shanghai 250040 ChinaInstitutes of Biomedical Sciences Fudan University Shanghai 200032 China;

    Department of General Surgery Huashan Hospital&Cancer Metastasis Institute&Institutes of Biomedical Sciences Fudan University Shanghai 250040 ChinaInstitutes of Biomedical Sciences Fudan University Shanghai 200032 China;

    Department of General Surgery Huashan Hospital&Cancer Metastasis Institute&Institutes of Biomedical Sciences Fudan University Shanghai 250040 ChinaInstitutes of Biomedical Sciences Fudan University Shanghai 200032 China;

    Department of General Surgery Huashan Hospital&Cancer Metastasis Institute&Institutes of Biomedical Sciences Fudan University Shanghai 250040 ChinaInstitutes of Biomedical Sciences Fudan University Shanghai 200032 China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 肿瘤学;
  • 关键词

    Hepatocellular carcinoma; RNA N6-methyladenosine,metabolism,bioinformatics,prognosis;

    机译:肝细胞癌;RNA N6-甲基腺苷;新陈代谢;生物信息学;预后;
  • 入库时间 2022-08-19 04:55:52
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号